It starts with cancer medicine. Or at least that’s where the blueprint comes from. A therapy designed to supercharge the body against tumors is being pivoted for a virus. And right now the early signs look wildly promising.
The Proof of Concept
Two people with HIV are currently free of detectable virus. No daily pills. Just a one-time infusion of their own engineered immune cells. One has been clean for nearly two years. The other for almost a year. They stopped their medication entirely.
Steven Deeks, the UC San Francisco professor who led this tiny trial, keeps it grounded. “These are early days,” he says at the ASGCT meeting in Boston. He’s careful not to sell the moon yet. If this works. If it’s safe. Then they can worry about making it affordable and scalable. But for now the proof of concept holds up.
This technique is called CAR-T therapy. You might have heard it. It’s saved thousands from stubborn cancers. Recently it even tamed some autoimmune disasters. Andrea Gramatica from amfAR sees the potential clearly. She notes this study offers the HIV field a tangible clue. Teaching the immune system to police the virus without drugs isn’t just theoretical. It’s achievable.
The Hard Road to a Cure
Since the early 80s we’ve chased a cure. We haven’t quite found it. Instead we found antiretroviral therapy (ART). It stops the virus. It keeps people alive near-normal lives. But the pills stay in the cabinet forever. For many that’s fine. For millions in low-income areas where the drugs don’t reach it’s not enough.
So far there are fewer than a dozen documented functional cures. Functional is the key word here. The virus isn’t gone. It’s hiding. Suppressed so deep the body ignores it and no meds are needed.
Every single one of those cases involved stem cell transplants. High risk. Intensive. Most used donors with a rare CCR5 mutation—a natural defense against HIV entry. Timothy Ray Brown. The Berlin patient. First one out of the blocks in 20081. But you can’t treat forty million people with bone marrow transplants meant for leukemia patients. Graft-versus-host disease is a nasty side effect. Not exactly scalable.
Engineering the Sentry
Boro Dropulić runs Caring Cross. His mission? Recreate that stem cell magic without the cancer diagnosis or the rare donor. He wants to engineer the outcome deliberately.
Cancer and HIV play similar tricks. Both hide from the immune system. In standard CAR-T the doctors take your T cells. They strip them from your blood. Then in a lab they stick chimeric antigen receptors onto the cells. New armor. These receptors let the cells lock onto specific protein targets. Find the bad guys. Destroy them.
For HIV the team engineered T cells to track two different parts of the virus. Double the targets harder to evade. “These cells remain like sentries,” Dropulić explains. The idea is simple vigilance. If the viral embers flicker these cells kill the spark before it burns.
Who Works and Why
Nine people tried the shot. All on ART first. They were split into two groups. The first three got only the cells no conditioning drug. A safety check. As expected their virus came back in weeks.
The next six got cells plus the conditioning drug to help the new immune troops expand. The results diverged sharply based on timing.
Those who started ART late in the game bounced back. Rapidly. They needed their pills again. But the three who started ART soon after diagnosis did better. Two still have zero virus. At 10 months. At 20 months. One managed two months of silence before the rebound. The body’s history matters. It seems the cleaner the slate the better the CAR-T works.
The Price of Hope
Even if this flies the funding committee likely won’t be happy right away. The current process is a logistical beast. Blood comes out. Cells are sent away for weeks of genetic tinkering. Then the cocktail goes back in. In the US that costs between $300000 and $475000 per shot.
Do the math. Forty million people need this. That’s billions in healthcare budget instantly vaporized. Not happening. Not like this.
But the labs are already iterating. They want to skip the external manufacturing entirely. Make the CAR-T cells inside the patient’s own veins. A single injection. No blood draw. No weeks of waiting in a sterile facility. Just a fix.
“One can make these cells in the body” says Deeks. He puts “in theory” there for legal cover mostly but the hope is real.
The tech is moving fast. The virus is moving slower. We are closer to a world without pills than most politicians will admit. The question remains though will we fix the economics before the patents lock everything up?
Only time will tell if the sentries stay posted.
